Manufacturer record
Genip Formulations Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Genip Formulations Pvt. Ltd (Himachal Pradesh) were declared Not of Standard Quality in October 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: GFTP25214, Esyfol-XT (Calcium Carbonate, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5 Phosphate Tablets) (exp Apr 2027). DTL, Bengaluru, Karnataka (state lab) found it not of standard quality: Test for Uniformity of weight? and does not conform to label claim with respect to ?Assay for Vitamin D3. Listed in the October 2025 alert.
Records by type
2 records linked to Genip Formulations Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Esyfol-XT (Calcium Carbonate, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5 Phosphate Tablets) | Batch GFTP25214Mfg May 2025 · Exp Apr 2027 | Test for Uniformity of weight? and does not conform to label claim with respect to ?Assay for Vitamin D3Assay | DTL, Bengaluru, KarnatakaState lab | Oct 2025 |
| Carbamazepine Tablets IP | Batch GFTP25317Mfg May 2025 · Exp Apr 2027 | Assay for CarbamazepineAssay | SDTL,Andhra Pradesh, VijayawadaState lab | Oct 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.